EMA Expired: Daklinza (daclatasvir dihydrochloride) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EMA indicates that Daklinza (daclatasvir dihydrochloride) has expired status as a medicinal product for chronic hepatitis C in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)

Snippet

Status: Expired. Therapeutic area: Hepatitis C, Chronic. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 24/07/2019. Accelerated assessment